Catálogo de publicaciones - libros

Palabras clave – provistas por la editorial

melanoma; invasion; WNT5A; MARCKS; phosphorylation; MANS peptide; nanoparticles; cell therapy; tumor microenvironment; sex/gender; sex-hormones; immunity; microRNAs; immunotherapy; BRAF-mutant melanoma; BRAF inhibitor; mechanism of action; targeted therapy; tumour microenvironment; plasmacytoid dendritic cells; lactate dehydrogenase; TLR; interferon; CXCL10; TPC2; HIPPO; SOCE; metastasis; essential oils; angiogenesis; apoptosis; uveal melanoma (UM); metastatic uveal melanoma (mUM); prognostication; adjuvant therapy; metastatic therapy; metastatic dormancy; liver-directed-therapies; targeted-therapy; combined therapy; protein tyrosine phosphatase; PTPs inhibitors; melanoma immune infiltrate; BRAF inhibitors; microenvironment; resistance; therapy; therapeutic resistance; exosomes; extracellular vesicles; diagnosis; prognosis; ctDNA; liquid biopsy; prediction; patient stratification; BRAF; arthralgia; rheumatoid arthritis; carbonic anhydrase; hedgehog; cyclopamine; small molecules; acetazolamide; motility; metalloproteinases; FAK; cancer; mucosal melanoma; nivolumab; pembrolizumab; ipilimumab; radiotherapy; cholinergic system; acetylcholine; muscarinic receptors; nicotinic receptors; melanoma metastasis; ShcD adaptor protein; amoeboid motility; Rac1; DOCK4; melanoma PDX; target therapy; cancer stem cells; slow cycling phenotype; drug resistance; OXPHOS; lipid metabolism; cancer associated fibroblast; melanomagenesis; biomarkers; checkpoint inhibitor; PD-1; melanoma markers; cytokines; machine learning; Support Vector Machine; principal component analysis; BCL2L10; STAT3; cytotoxicity; survival; ABT-737; Bcl-2 family; ML258; HuR; MITF; metastases; siRNA; n/a